First-in-human study of LY3039478, an oral Notch signaling inhibitor in advanced or metastatic cancer. (December 2016) - Massard, C.; Azaro, A.; Soria, J.C.; Lassen, U.; Le Tourneau, C.; Smith, C.; Ohnmacht, U.; Oakley, G.; Patel, B.K.R.; Yuen, E.S.M.; Benhadji, K.A.; Rodon, J.